Geron jumps as its J&J-partnered cancer drug shows promise in Phase II

Damian Garde Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as ...

Ka-Ching: F. Michael Ball cashes out of Hospira with $91.1M

Eric Palmer Early indications that CEO F. Michael Ball would cash out with $ 80 million when Pfizer completed its buyout of Hospira were clearly off the mark. Instead ...

Volatile valuations make biotech a haven for short sellers

Damian Garde The years-long glut of biotech IPOs has flooded the public markets with high-risk life sciences companies, and shorts have taken a particular interest in those newly public ...

UPDATED: AstraZeneca scores FDA nod for long-term Brilinta use

Carly Helfand AstraZeneca's blood thinner Brilinta is officially one step closer to living up to the British pharma's $ 3.5 billion ambitions. The FDA has handed down an approval ...

Genzyme vets raise $37.5M for a new cancer biotech

Damian Garde The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $ 37.5 million to fund its work on new cancer treatments. FierceBiotech News

India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

Eric Palmer India's Cipla has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative ...

MD Anderson adds Cellectis to a crush of immunotherapy collaborations

John Carroll The MD Anderson Cancer Center in Houston is becoming the preferred partner of choice among a growing group of immuno-oncology players looking to develop a new generation ...

GSK inks exclusive vaccines deal with new GlycoVaxyn affiliate

Amirah Al Idrus When GlaxoSmithKline bought out GlycoVaxyn for $ 190 million earlier this year, it gained a set of early-stage vaccines and commissioned GlycoVaxyn's team ...

LimmaTech sets up as de facto GSK vaccine R&D unit in wake of $190M buyout

Nick Paul Taylor LimmaTech Biologics, a spillover from the $ 190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting ...

Trial set for Pfizer in Protonix Medicaid rebate case it inherited

Eric Palmer A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $ 2 billion. That is the potential liability Pfizer faces for a federal ...

Celyad set to scale up China-focused R&D activities after linking with Medisun

Nick Paul Taylor Cell therapy specialist Celyad is set to add Hong Kong to the clinical trial program of its ischemic heart failure treatment, giving its newly recruited partner Medisun ...

European pharma lobby says ‘non’ to French funding for off-label Avastin

Emily Wasserman The French government recently said "oui" to Roche's ($ RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS